Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

CQDM*

$20.8 million for 2009-17
About   |   News   |   Features   |   Videos
CQDM

Number of partners
145

Partner contributions
$53.7 million

Headquarters
Montréal, Quebec

President and CEO
Diane Gosselin Diane Gosselin

Board chair
Richard Fajzel Richard Fajzel
CEO, Exactis Innovation

Strengthening business ties between small biotech and big pharma


The opportunity

The high risks and escalating costs of drug development have made it difficult for early-stage biotech companies to attract financing. That challenge, combined with imminent patent cliffs, has triggered a major restructuring of the global pharmaceutical industry as companies race to decrease risk and become more capital efficient. Through CQDM, Canada has developed proven investment models that are reducing risk through open innovation and collaborative R&D with pharmaceutical companies, early-stage biotech companies, academia and public bodies. This allows companies to move beyond a fee-for-service model, retain equity and ownership of their intellectual property, and grow their operations in Canada.

How CQDM is seizing the opportunity

CQDM is sponsored by nine of the world’s largest pharmaceutical companies (Merck, Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Eli Lilly Canada, Janssen, Novartis Pharma Canada and Sanofi Canada) and the governments of Quebec and Canada. It provides critical funding and a neutral ground where pharmaceutical and biotech companies collaborate with academic researchers, graduate students, research institutions, venture capitalists, and governments to accelerate the development and validation of precompetitive research tools and platforms. Nearly 120 top scientists from pharma company sponsors also act as mentors for CQDM projects. This forges strong links between big pharma, small biotech and academic scientists, while ensuring that research is aligned with each company’s needs.

Among the results

  • Eight startups have been launched as a result of CQDM-supported research, including Encycle Therapeutics, whose platform technology has generated a library of more than 1,400 nacellins, cyclical molecules with a greater potential for cell permeability and oral bioavailability.
  • A CQDM-financed project realized a proof-of-concept of a revolutionary approach that uses magneto-aerotactic bacteria to deliver anti-cancer drugs to cells at the core of tumours that are deprived of oxygen.
  • CQDM is partnering with the German Federal Ministry of Economic Affairs and Energy to fund collaborative projects between Canada and Germany. The first project to receive funding is for an integrated platform for the study of the endoplasmic reticulum, which helps cells manufacture and distribute substances such as proteins.
  • A CQDM-financed project developed PulmoBlind, the first safe, sensitive and non-invasive molecular imaging agent designed for early diagnosis and monitoring of pulmonary hypertension. The new pharmaceutical product will soon undergo Phase III study.

Connect with CQDM


* (formerly known as Quebec Consortium for Drug Discovery)

 

News
July 4, 2014
Features
Open innovation, creative partnerships and profitable collaborations
April 17, 2014
The high risks and escalating costs of drug development have made it difficult for early-stage biotech companies to attract financing. Those that succeed often have to relinquish too much equity; those that don’t may move out of Canada or close up shop. These challenges, combined with imminent patent cliffs, have triggered a major restructuring of the global pharmaceutical industry as companies race to decrease risk and become more capital efficient. Read more
Building Canada's Strengths: Drug Discovery and Commercialization
April 17, 2014
Developing new drugs is a long, complex and expensive process. The NCE supports several models that are helping reduce the risk and accelerate the commercialization of medical innovations that will improve health-care delivery and patient care in Canada and abroad. Read more
Building the world's largest life sciences corridor between Quebec and Ontario
August 1, 2013
In 2011, the Ontario and Quebec governments established the Ontario-Quebec Life Sciences Corridor, enabling the two provinces to become one of the largest bioclusters in the world. One of its priorities is to enhance opportunities for investment, partnership and collaboration in life sciences research, innovation and commercialization. Read more
Quebec and France team up for better biomedical research
November 2, 2011
An international partnership between a non-profit organization based in Quebec and a health cluster in France is taking shape in the health and therapeutic innovation sector. The Quebec Consortium for Drug Discovery (CQDM) is collaborating with Alsace BioValley in order to develop new tools to facilitate the discovery of safer and more effective drugs. Read more
Videos
Watch Video
Protein trafficking and misfolding under scrutiny
May 25, 2016
Watch Video
Gala Prix Performance 2014 | Diane Gosselin, PhD, M.B.A
January 6, 2015
This link will take you to another Web site Watch Video (available in French only)
Watch Video
CQDM video
December 2, 2013